Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational Cohort - PubMed
4 hours ago
- #Mortality
- #Hepatitis C
- #Direct-acting antivirals
- Study examines long-term mortality and risk factors post-HCV cure using DAAs in a multinational cohort.
- Includes 10,034 patients with sustained virological response (DAA-SVR), stratified by cirrhosis status.
- Overall mortality rate was 10.4 per 1000 patient-years, with decompensated cirrhosis showing the highest rate (60.0 per 1000 PY).
- 5-year cumulative survival was 95.1% overall, but only 73.9% for decompensated cirrhosis.
- Non-liver-related deaths were predominant in non-cirrhosis and compensated cirrhosis, while liver-related deaths dominated in decompensated cirrhosis.
- Key risk factors for higher mortality included age >65, male gender, cirrhosis (especially decompensated), and baseline diabetes mellitus.